Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0JQYKU
ADC Name	Anti-CD33AB-Compound (Ib)
Synonyms	Anti CD33AB Compound (Ib) Click to Show/Hide
Organization	Orum Therapeutics, Inc.
Drug Status	Investigative
Indication	In total 1 Indication(s) Acute myeloid leukaemia [ICD11:2A60] Investigative
Drug-to-Antibody Ratio	3.13
Structure
	3D MOL	2D MOL
Antibody Name	Anti-CD33AB		Antibody Info
Antigen Name	Myeloid cell surface antigen CD33 (CD33)		Antigen Info
Payload Name	NeoDegrader P1		Payload Info
Therapeutic Target	Protein cereblon (CRBN)		Target Info
Linker Name	Anti-CD33AB-Compound (Ib) linker

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≈ 57.39	%	MV4-11 cells	Childhood acute monocytic leukemia
Tumor Growth Inhibition value (TGI)	≈ 99.61	%	MV4-11 cells	Childhood acute monocytic leukemia

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 57.39% (Day 46)	Positive CD33 expression (CD33+++/++)
Method Description	1 x 10⁷ MV411 human acute monocytic leukemia cells in 50% Matrigel were injected subcutaneously in the flank of the mice (0.1 mL/mouse). The mice were dosed with anti-CD33 antibody-neoDegrader conjugates and vehicle control once tumors reached an average size of 100-150 mm³. The stock solutions of CD33AB-Compound (lb) was diluted with vehicle, which provided, 2.94 mg/kg in a dosing volume of 10 mL/kg (0.2 mL per 20 g mouse). Click to Show/Hide
In Vivo Model	MV411 CDX model
In Vitro Model	Childhood acute monocytic leukemia	MV4-11 cells		CVCL_0064
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 99.61% (Day 18)	Positive CD33 expression (CD33+++/++)
Method Description	1 x 10⁷ MV411 human acute monocytic leukemia cells in 50% Matrigel were injected subcutaneously in the flank of the mice (0.1 mL/mouse). The mice were dosed with anti-CD33 antibody-neoDegrader conjugates and vehicle control once tumors reached an average size of 100-150 mm³. The stock solutions of CD33AB-Compound (lb) was diluted with vehicle, which provided, 2.94 mg/kg in a dosing volume of 10 mL/kg (0.2 mL per 20 g mouse). Click to Show/Hide
In Vivo Model	MV411 CDX model
In Vitro Model	Childhood acute monocytic leukemia	MV4-11 cells		CVCL_0064

References

Ref 1	Neodegrader conjugates; 2021-10-07.